Starton Therapeutics is developing STAR-LLD for use in blood cancers including CLL.
Starton continuous delivery approach and results
Current treatment landscape and opportunities in CLL
STAR-LLD Phase 1/2 strategy
Dr. Jamie Oliver, Chief Medical Officer
Dr. Asher Chanan-Khan, CLL Lead, Co-Chair Hematologic Malignancies at Mayo Clinic Jacksonville
Pedro Lichtinger, Chief Executive Officer